Understanding Pancreatic Development and Diabetes Using Patient-Specific iPS Cells


Pancreatic progenitor cells derived from human embryonic stem or induced pluripotent stem cells hold tremendous potential for modeling pancreatic development and disease, as well as for regenerative therapies addressing degenerative conditions like diabetes. The ability to direct differentiation of pancreatic progenitor cells to specific endocrine cell types has led researchers to propose human pluripotent stem cells as an unlimited source of insulin-producing beta cells for studying and treating diabetes. In this webinar, Dr. Ray Dunn and Dr. Jamie Trott (A*STAR Institute for Medical Biology, Singapore) present their data on generating pancreatic progenitors and beta cells from diabetic-patient-derived induced pluripotent stem cells.
Publish Date: April 18, 2016

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.